Velaglucerase
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 102 publications
Establishment of an N-Glycan Profiling Method for Three ERT Enzymes Used in Gaucher Disease Therapy.
Establishment of an N-Glycan Profiling Method for Three ERT Enzymes Used in Gaucher Disease Therapy.
Journal: Molecules (Basel, Switzerland)
Published: April 13, 2026
A 53-week, open-label phase IIIb study of velaglucerase alfa in Chinese patients with type 1 Gaucher disease: Safety, efficacy, and pharmacokinetics.
Journal: Molecular genetics and metabolism reports
Published: March 02, 2026
Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical Studies.
Journal: Journal of clinical medicine
Published: January 19, 2026
Quantitative and Comparative Assessment of Recombinant Human β-Glucocerebrosidase Uptake Bioactivity Using a Stable hMMR-Expressing CHO Cell Model.
Journal: Molecules (Basel, Switzerland)
Published: November 27, 2025
Bone involvement in Gaucher disease: Data from a North African registry.
Journal: Reumatologia clinica
Published: July 17, 2025
Enzyme replacement therapy in infants and very young children with Gaucher disease using velaglucerase alfa: a single-center experience.
Journal: Frontiers in pediatrics
Published: April 17, 2025
Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?
Journal: PharmacoEconomics - open
Published: April 08, 2025
Investigating the therapeutic profile of velaglucerase alfa in paediatric patients with Gaucher disease: a systematic review across all paediatric age groups.
Journal: Orphanet journal of rare diseases
Published: February 26, 2025
Effective encapsulation of therapeutic recombinant enzyme into polymeric nanoparticles as a potential vehicle for lysosomal disease treatment.
Journal: International journal of biological macromolecules
Published: August 14, 2024
Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry.
Journal: Journal of clinical medicine
Published: April 19, 2024
A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study.
Journal: Journal of clinical medicine
Published: April 08, 2024
Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry.
Journal: Journal of clinical medicine
Published: March 25, 2024
Last Updated: 06/30/2026